Skip to content
Politically.com Search all
Menu

2025 · 4th Quarter (Oct 1 - Dec 31)

ELEVANCE HEALTH, INC.

Filed by MEHLMAN CONSULTING, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
4th Quarter - Report
Posted
Jan 20, 2026
Income
$90,000.00
Expenses
Not reported
Filing UUID
2b68637b-09e1-48b8-a43b-28cd095f9b6d
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Prescription Drug Pricing.

TAX · Taxation/Internal Revenue Code

Issues related to advanced premium tax credits. PL 119-21, An act to provide for reconciliation pursuant to title II of H. Res. Con. 14.

HCR · Health Issues

Issues related to health insurance price transparency. Issues related to prescription drug costs and delivery. PL 119-21, An act to provide for reconciliation pursuant to title II of H. Res. Con. 14.

MMM · Medicare/Medicaid

Medicare Advantage, Medicare Part D, Medicaid Managed Care. Issues related to prescription drug costs and delivery. PBM Reform issues. PL 119-21, An act to provide for reconciliation pursuant to title II of H. Res. Con. 14.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.